Tolerance of Rilmenidine and its combination with amlodipine in hypertensive patients (according to ALTAIR study)
https://doi.org/10.18705/1607-419X-2006-12-1-80-84
Abstract
The aim of the study was lo evaluate tolerance of rilmenidine and its combination with amlodipine in ALTAIR study population. The study included 677 patients. 610 (90.4 %) completes it successfully. 126 adverse events have been observed, but only in 4.4 % cases it lead to therapy discontinuation. Adverse events were most frequent on i week visit, later due to excluding of some patients and disappearance of several adverse events its rate. The most frequent adverse effect was dry mouth which was registered in 64 (9.5 %) patients. In conclusion, analysis of ALTAIR data indicates that rilmenidine is well tolerated taking alone оr in combination with amlodipine in patients with mold-to-moderate hypertension. Moreover, rilmenidine therapy is accompanied by improvement of quality of life.
About the Authors
E. V. Shlyakhto
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
A. O. Konradi
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
References
1. Вriсса G., Dontenwill M., Molines A., Feldman J., Tibirica E., Belcourt А., Bousquet P. Rilmenidine selectivity for imidazoline receptors in human Brain. Eur J Pharmacol. 1989: 163: 373-377.
2. Luccioni R. Efficacy and Acceptability of Rilmenidine in 18235 Patients over One Year. Presse Med., 1995; 124: 1827-64.
3. Ostermann G., Brisgand B., Schmitt J., Fillastre J.P. Efficacy and acceptability of rilmenidine for mild to moderate systemic hypertension. Am J Cardiol. 1988 Feb 24; 61 (7): 76D-80D.
4. Schwartz V.W., Kandziora J. Langzeiter fahrungen mit Moxonidin, einem neuen Antihypertensivum. Fortschrile der Medizin 1990: 108: 64-70.
5. Prochard B.N., Graham B.R. It-imidazoline agonista. General clinical pharmacology of imidazoline receptors. Draus and Aging 200: 17:133-159.
6. WHO. Adherence in long-term therapies: evidence far action. Geneva: WHO: 2003.
7. Sides G.D., Leschinger M.I., Walenta R. et al. The tolerability and adverse event profile of moxonidine. Rev Contemp Pharmacother 1998; 9: 491-9.
8. Schachter M., Luszick J., Jager B. et al. Safety arid tolerability of moxonidine in the treatment of hypertension. Drug Saf 1998: 19: 191-203.
9. Pillion G., Fevrier B., Codis P., Schutz D. Long-term control of blood pressure by rilmenidine in high-risk populations. Am J Cardiol. 1991 Dec 22:74 (13): 58A-65A.
10. Ю.Р. Кашерининов, А.А. Шаваров, С.В. Виллевальде, А.О. Конради, Е.В. Шляхто качество жизни у больных гипертонической болезнью на фоне терапии рилменидином в сравнении с атенололом. Артериальная гипертензия 2004: 10: 78-84.
11. Passeron J., Guillet C.Treatment with rilmenidine 1 mg per day: time-lag to maximum response. A multicenter ambulatory study. Le Groupe Francais d'etude Multicentrique d'Hyperium Presse Med. 1992: 21; 2089-2093.
Review
For citations:
Shlyakhto E.V., Konradi A.O. Tolerance of Rilmenidine and its combination with amlodipine in hypertensive patients (according to ALTAIR study). "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2006;12(1):80-84. (In Russ.) https://doi.org/10.18705/1607-419X-2006-12-1-80-84
Views:
1650
Email this article 